Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Osteoporosis Clinical Trial

Official title:

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02418273
• Other study ID #: 1504269855
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: August 1, 2019
• Est. completion date: June 2021

Study information

• Verified date: December 2019
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate denosumab as a novel treatment for bone loss in children treated with glucocorticoids for rheumatic disorders. This is a pilot Phase 1/2, randomized open-label, 12-month clinical trial of denosumab to assess its effect on bone resorption markers and bone mineral density (BMD) in children with rheumatic disorders, age 4 to 16 years, recruited within 1 month of starting a chronic systemic glucocorticoid regimen. Primary outcomes include suppression of bone turnover markers and safety assessments. Secondary outcomes include changes in bone density as measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) densitometry at the radius and tibia.

Description:

The purpose of this study is to evaluate denosumab as a novel treatment for bone loss in children treated with glucocorticoids for rheumatic disorders. Children with rheumatic disorders are at risk for low bone density and fractures from the inflammatory effects of the underlying disease, and also from direct effects of glucocorticoids on bone. This is a pilot Phase 1/2, randomized open-label, 12-month clinical trial of denosumab to assess its effect on bone resorption markers and BMD in children with rheumatic disorders, age 4 to 16 years, recruited within 1 month of starting a chronic systemic glucocorticoid regimen. Two different sequential doses will be administered to the intervention group and evaluation for safety and efficacy will be conducted at study visits. Primary outcomes include suppression of bone turnover markers and safety assessments. Secondary outcomes include changes in bone density as measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) densitometry at the radius and tibia.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 16 Years

Eligibility

Inclusion Criteria:

1. Age 4 to 16 years of age.

2. Diagnosis of one of the following by a rheumatologist using standard criteria:

juvenile dermatomyositis, juvenile idiopathic arthritis, systemic arthritis, seronegative or seropositive polyarthritis, psoriatic arthritis, systemic lupus or systemic vasculitis.

3. Within 1 month of initiating glucocorticoids =0.5 mg/kg prednisone equivalent daily, planned for = 6 months.

4. BMD by DXA with Z-score < 0.0 on screening at lumbar spine or total body less head (TBLH).

Exclusion Criteria:

1. Previous treatment with a bisphosphonate, or other osteoporosis medication.

2. Metabolic bone disorders besides glucocorticoid-induced osteoporosis; other disorders treated with systemic glucocorticoids (inflammatory bowel disease, severe pulmonary disease, nephrotic syndrome, etc.).

3. Intent to treat with a tumor necrosis factor inhibitor or Interleukin 6 receptor antagonist during the first 6 months.

4. Glomerular filtration rate < 30ml/min [pediatric estimated glomerular filtration rate = 0.413*(height/serum creatinine)] 75

5. Planned orthopedic or other major surgery during the course of the study (at the time of enrollment)

6. Significant dental caries, or plans to undergo invasive oral procedures during the subsequent 12 months.

7. Known allergy to latex (drug packaging includes a natural rubber stopper), fructose intolerance or other denosumab contraindication.

8. 25-hydroxyvitamin D (25OHD) level < 32 ng/dl. Subjects with 25OHD <32 ng/ml may be given cholecalciferol and rescreened.

9. Hypocalcemia at screening (total serum calcium < 8.5 mg/dl after correction for albumin level).

10. Chronic ventilator dependence, or other conditions increasing risk of participation.

11. Pregnancy, or refusal to use acceptable contraception or abstain during the protocol (post-pubertal female).

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Juvenile
• Dermatomyositis
• Glucocorticoid-induced Osteoporosis
• Juvenile Rheumatoid Arthritis
• Lupus Erythematosus, Systemic
• Osteoporosis
• Polyarthritis
• Systemic Lupus Erythematosis
• Vasculitis

Intervention

Drug:
• denosumab
These subjects will receive two doses of denosumab.

Locations

Country	Name	City	State
United States	Indiana University School of Medicine	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in bone turnover marker (N-telopeptide (NTX) /creatinine ratio).		2 weeks, 1 month, 2 month, 3 month after each dose day.
Secondary	The duration of suppression of the NTX/creatinine ratio		up to six months after each dose day
Secondary	The changes in bone specific alkaline phosphorus		From baseline to 1 week, 1,3,6 months after each dose day
Secondary	Changes of BMD spine Z-scores		12 month
Secondary	Changes of BMD Total body less head (TBLH) Z-scores		12 month
Secondary	Changes of volumetric BMD on peripheral quantitative computed tomography		12 month
Secondary	Changes of polar strength-strain index at tibia		12 month
Secondary	Changes of polar strength-strain index at radius		12 month
Secondary	Changes in bone strength index for compression at tibia.		12 month
Secondary	Changes in bone strength index for compression at radius		12 month
Secondary	The relationships of Interleukin 6 to baseline NTX/creatinine ratio		baseline visit
Secondary	The relationships of Interleukin 6 to baseline DXA		baseline visit
Secondary	The relationships of Interleukin 6 to baseline pQCT variables.		baseline visit
Secondary	The relationships of receptor activator of nuclear factor-kappa B ligand (RANKL) to baseline NTX/creatinine ratio		baseline visit
Secondary	The relationships of receptor activator of nuclear factor-kappa B ligand (RANKL) to baseline BMD		baseline visit
Secondary	The relationships of receptor activator of nuclear factor-kappa B ligand (RANKL) to baseline volumetric BMD		baseline visit
Secondary	Dose limiting toxicities (DLTs), including hypocalcemia		3 days, 1 week, 2, week, month 3,4,5,6 after each dose; or any other visits.